AIP Seulement trois entreprises du bois certifiées en Côte d’Ivoire (Syndicat) AIP Visite d’Etat dans la Marahoué : 20.000 personnes attendues au meeting du président Ouattara à Sinfra AIP Visite d’Etat dans la Marahoué: Le stade de Douafla prêt à accueillir le premier meeting du Président Ouattara à Sinfra AIP La délimitation du territoire d’un village, « une mine d’or », selon un expert en foncier GNA GenCED calls for anti-sexual harassment law, policies at work places GNA Clear drains, gutters to prevent flooding – GMet GNA Auxiliary staff take over nurses’ roles in Hohoe GNA Iranian envoy bids farewell to President Akufo-Addo GNA CSIR-SARI Scientists commended for maintaining protocols GNA President Akufo-Addo launches Pan African Heritage Museum

Danadams to increase ARV portfolio from monotherapy to combination therapy

  7 Août      17        Santé (7420),


Accra, Aug. 7, GNA- The Research and Development (R&D) Department of the Danadams Pharmaceuticals Industry Limited has said it is working to increase the Antiretroviral drug’s portfolio from monotherapy to combination therapy.

The move is in line with World Health Organisations recommendation to introduce drug regimes with high potency, lower toxicity and resistance, lower cost to improve the quality of care of people living with HIV.

Mr Prince Yamoah, Chief Executive Officer of Danadams Pharmaceuticals Industry, speaking in an interview with the Ghana News Agency said the soon to be ready product combined a number of tables that patients used to take separately.

“With the new formulation instead of taking three to four tablets at a particular time, the patient will only take one tablet to perform the same function. That makes the drug friendly to the patient,” he explained.

Mr Yamoah said the Company through its R&D with the needed support would continue to explore innovative ways to produce quality products that met international standards.

Danadams, which started operation in Ghana with a few anti-retroviral drugs, now has more than 42 different brands, including anti-malarials, anti-bacterials, analgesics anti-helmintics

He hinted that the Company would soon start the production of syrup medications in addition to the oral solid dosage production line.

Mr Yamoah said the Company had acquired a syrup production plant, which would be installed by the end of the year.

“Our R&D has already developed new syrup formulations…together with our engineers we will start installation and qualification in the next few months and once that is done production will continue,” he said.

He said the Company’s strategy on the Anti- malaria was to make its DANMETHER both in tablet, Granules powders in sachet, and bottles a household name.

In response to COVID-19, the Chief Executive Officers said the R&D would also introduce Hydroxychloroquine, an oral tablet on to the market soon.

He added that the Company had already begun producing hand sanitizers in commercial quantities.

Mr Yamoah said Danadams Pharmaceutical aside its offices in Togo, Benin, Cote d’Ivoire, Burkina Faso, had created new Business Development and Customer Care Unit that was working assiduously to expand its frontiers to Ethiopia and Rwanda.

Dans la même catégorie